Melatonin for the Treatment of DEE-SWAS
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Melatonin.
- Who it may be relevant to
- Registry conditions: CSWS, Developmental and/or Epileptic Encephalopathies, Electrical Status Epilepticus in Sleep. Basic parameters: 5 years — 17 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Melatonin for the Treatment of Developmental/Epileptic Encephalopathy With Spike Wave Activation In Sleep (DEE-SWAS; Formerly ESES)
Overview
The goal of this study is to learn if melatonin, a naturally produced substance, can help to treat some of the symptoms of DEE-SWAS, a type of epilepsy that causes children to lose skills and development. It will look at doses of melatonin that are higher than most people use. The study will look at the safety of melatonin in patients with DEE-SWAS The study will look at the ways melatonin affects abnormal brain activity on a study called an EEG. The study will look at the ways melatonin affects normal brain activity that occurs in sleep.
Interventions
- Drug Melatonin
Melatonin will be used in single fixed dose as described
Primary outcome measures
- Adverse Events [Time frame: Within 24 hours of dose administration]
- Side effects [Time frame: Within 24 hours of dose administration]
Secondary outcome measures (3)
- Spike wave index (SWI) [Time frame: Within 24 hours of dose administration]
- Sleep spindle [Time frame: Within 24 hours of dose administration]
- Salivary melatonin pharmacokinetics [Time frame: 24 hours prior to intervention and 24 hours following intervention]
Eligibility criteria
Inclusion criteria
Clinic Dx of DEE-SWAS
- Dx of DEE-SWAS by a board-certified pediatric neurology/epileptologist Clinical history of delayed milestones in at least 1 category, regression of milestones in at least 1 category, and/or failure to progress in milestones in at least 1 category
- Abnormal baseline neuropsychiatric testing consistent with Dx Abnormal EEG
- Epileptiform abnormalities (spike, polyspike, sharp) in at least 1 head region
- Increase by 2-fold of epileptiform abnormalities during NREM sleep as compared to wakefulness
- SWI of ≥50% in at least one head region on overnight EEG
Exclusion criteria
- Allergic to ingredients in study drug Melatonin
- Hypoallergenic plant fiber (cellulose)
- Active use of the medication viloxazine
- History of known cardiac rhythm abnormalities, heart failure or decreased EF <30%
- History of known pulm requiring oxygen or invasive positive pressure ventilation. Patients with non-invasive PPV (e.g. CPAP) due OSA w/o 02 requirement, rate, or DX of CSA, on stable pressure settings for >3 mnths will not be excluded.
- History of liver dysf OR AST/ALT/AlkPhos >2.5 ULN w/i year. If lab value meeting exclusion between 3-12 months, a repeat lab value < 2.5 ULN will be considered for inclusion
- Post-menarchal participants. of childbearing potential with a positive urine pregnancy test
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07221968 · IRB00478764